Literature DB >> 25078136

Activators of PKM2 in cancer metabolism.

Steven L Warner1, Kent J Carpenter, David J Bearss.   

Abstract

Pyruvate kinase converts phosphoenolpyruvate to pyruvate, catalyzing the rate-limiting step of glycolysis. The M1 isoenzyme of pyruvate kinase (PKM1) is found in adult tissues; whereas, PKM2 is a splicesome variant found in embryonic and cancer cells. PKM2 expression in malignant cells is a result of the tumor microenvironment and is responsible for maintaining a glycolytic phenotype. PKM2 has other nonmetabolic functions in malignant cells, including transcriptional coactivation and protein kinase activity. PKM2 activators have antitumor properties by inducing tetramerization of two PKM2 dimers causing PKM2 to function like PKM1. Restoring PKM2 to PKM1-like levels of activity causes reversal of the Warburg effect in cancer cells. PKM2 activators have therapeutic potential in the treatment of cancer and other metabolic diseases.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25078136     DOI: 10.4155/fmc.14.70

Source DB:  PubMed          Journal:  Future Med Chem        ISSN: 1756-8919            Impact factor:   3.808


  16 in total

Review 1.  Role of PKM2 in directing the metabolic fate of glucose in cancer: a potential therapeutic target.

Authors:  Gustav van Niekerk; Anna-Mart Engelbrecht
Journal:  Cell Oncol (Dordr)       Date:  2018-05-24       Impact factor: 6.730

Review 2.  Pyruvate Kinase M2: a Metabolic Bug in Re-Wiring the Tumor Microenvironment.

Authors:  Mohd Rihan; Lakshmi Vineela Nalla; Anil Dharavath; Amit Shard; Kiran Kalia; Amit Khairnar
Journal:  Cancer Microenviron       Date:  2019-06-10

3.  MYCN controls an alternative RNA splicing program in high-risk metastatic neuroblastoma.

Authors:  Shile Zhang; Jun S Wei; Samuel Q Li; Tom C Badgett; Young K Song; Saurabh Agarwal; Cristian Coarfa; Catherine Tolman; Laura Hurd; Hongling Liao; Jianbin He; Xinyu Wen; Zhihui Liu; Carol J Thiele; Frank Westermann; Shahab Asgharzadeh; Robert C Seeger; John M Maris; Jamie M Guidry Auvil; Malcolm A Smith; Eric D Kolaczyk; Jason Shohet; Javed Khan
Journal:  Cancer Lett       Date:  2015-12-10       Impact factor: 8.679

4.  PKM2 and other key regulators of Warburg effect positively correlate with CD147 (EMMPRIN) gene expression and predict survival in multiple myeloma.

Authors:  S Panchabhai; I Schlam; S Sebastian; R Fonseca
Journal:  Leukemia       Date:  2016-12-27       Impact factor: 11.528

5.  Impact of diabetes on promoting the growth of breast cancer.

Authors:  Ping-Chieh Chou; Hyun Ho Choi; Yizhi Huang; Enrique Fuentes-Mattei; Guermarie Velazquez-Torres; Fanmao Zhang; Liem Phan; Jaehyuk Lee; Yanxia Shi; James A Bankson; Yun Wu; Huamin Wang; Ruiying Zhao; Sai-Ching Jim Yeung; Mong-Hong Lee
Journal:  Cancer Commun (Lond)       Date:  2021-02-20

6.  Pyruvate Kinase M2 and Lactate Dehydrogenase A Are Overexpressed in Pancreatic Cancer and Correlate with Poor Outcome.

Authors:  Goran Hamid Mohammad; S W M Olde Damink; Massimo Malago; Dipok Kumar Dhar; Stephen P Pereira
Journal:  PLoS One       Date:  2016-03-18       Impact factor: 3.240

7.  High Expression of Pyruvate Kinase M2 is Associated with Chemosensitivity to Epirubicin and 5-Fluorouracil in Breast Cancer.

Authors:  Yang Lin; Feng Lv; Fangfang Liu; Xiaojing Guo; Yu Fan; Feng Gu; Jun Gu; Li Fu
Journal:  J Cancer       Date:  2015-09-15       Impact factor: 4.207

Review 8.  Tumor pyruvate kinase M2 modulators: a comprehensive account of activators and inhibitors as anticancer agents.

Authors:  Bhagyashri Rathod; Shivam Chak; Sagarkumar Patel; Amit Shard
Journal:  RSC Med Chem       Date:  2021-05-17

9.  PKM2 and cancer: The function of PKM2 beyond glycolysis.

Authors:  Gaochao Dong; Qixing Mao; Wenjie Xia; Youtao Xu; Jie Wang; Lin Xu; Feng Jiang
Journal:  Oncol Lett       Date:  2016-01-29       Impact factor: 2.967

10.  Up-regulation of PKM2 promote malignancy and related to adverse prognostic risk factor in human gallbladder cancer.

Authors:  Wei Lu; Yang Cao; Yijian Zhang; Sheng Li; Jian Gao; Xu-An Wang; Jiasheng Mu; Yun-Ping Hu; Lin Jiang; Ping Dong; Wei Gong; Yingbin Liu
Journal:  Sci Rep       Date:  2016-06-10       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.